# Challenges in managing recurrent luminal A breast cancer: a case study

## TL;DR

A young woman with Luminal A breast cancer experienced rapid disease progression and death, highlighting the need for better treatment strategies for younger patients.

## Contribution

Highlights atypical aggressiveness of Luminal A breast cancer in young patients and calls for tailored treatment approaches.

## Key findings

- A 35-year-old patient with Luminal A breast cancer had multiple recurrences and died within 2 years.
- Younger patients with Luminal A breast cancer may have more aggressive disease than previously assumed.
- Current treatment approaches may be insufficient for younger individuals with this subtype.

## Abstract

Breast cancer, a leading cause of cancer-related mortality in women worldwide, exhibits diverse molecular subtypes with varying prognostic implications. Luminal A breast cancer, characterised by estrogen receptor positivity, progesterone receptor positivity and human epidermal growth factor receptor 2 negativity, typically has a favourable prognosis. However, we present a case of a 35-year-old female diagnosed with Luminal A breast cancer who experienced multiple recurrences and succumbed to the disease within 2 years of diagnosis. Despite initial treatment modalities, including surgery, chemotherapy and hormonal therapy, the patient faced relentless disease progression, highlighting the atypical clinical course observed in younger individuals with Luminal A breast cancer. This case underscores the discrepancy in prognosis between younger and older patients with Luminal A breast cancer, emphasising the need for tailored treatment approaches to address the challenges associated with disease recurrence and aggressiveness in younger populations. Further research is warranted to explain the underlying mechanisms driving the aggressive behaviour of Luminal A breast cancer in young patients and to develop targeted therapeutic strategies to improve outcomes in this population.